U.S. increases order of Moderna mRNA COVID-19 vaccine to 300M doses

By The Science Advisory Board staff writers

January 27, 2021 -- Moderna is in discussion with the U.S. government for the purchase of an additional 100 million doses of its messenger RNA (mRNA) COVID-19 vaccine, mRNA-1273, for delivery in the third quarter of 2021.

To date, the U.S. has agreed to purchase 200 million doses of the Moderna COVID-19 vaccine, and this new purchase would bring the total to 300 million doses. The company plans on using its U.S.-based manufacturing capabilities to supply the vaccine to the U.S. government.

FDA moves quickly toward formal Moderna EUA decision
The U.S. Food and Drug Administration (FDA) has informed Moderna that it will work rapidly toward the issuance of an emergency use authorization (EUA)...
Europe buys 80M more doses of Moderna COVID-19 vaccine
The European Commission has exercised an option to purchase an additional 80 million doses of Moderna's messenger RNA (mRNA) COVID-19 vaccine candidate,...
FDA issues EUA for Moderna COVID-19 vaccine
Just one day after a favorable committee recommendation, the U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for...
FDA committee votes favorably for Moderna COVID-19 vaccine EUA
Moderna's messenger RNA (mRNA) COVID-19 vaccine candidate, mRNA-1273, received a favorable recommendation on December 17 from an advisory committee to...
U.S. to pay $1.5B for Moderna's COVID-19 vaccine
The U.S. government awarded a maximum $1.525 billion contract to Moderna to secure 100 million doses of its messenger RNA COVID-19 vaccine.

Copyright © 2021 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter